Skip to content
    Clinical Trials

    Elacestrant plus everolimus shows benefit in advanced breast cancer trial

    Rugo et alClin Cancer Res

    Elacestrant plus everolimus shows benefit in advanced breast cancer trial
    Findings from the Phase 1b/2 ELEVATE umbrella trial demonstrate clinical activity and safety for the all-oral combination of elacestrant, an oral selective estrogen receptor degrader (SERD), plus everolimus in patients with estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced breast cancer (ABC). Enrolled patients had disease progression on 1 to 2 prior lines of endocrine therapy combined with a CDK4/6 inhibitor and no prior chemotherapy for advanced disease. In the Phase 1b portion (n=23), the recommended Phase 2 dose (RP2D) was identified as elacestrant 345 mg daily combined with everolimus 7.5 mg daily.
    The Phase 2 cohort (n=50) evaluated patients with high-risk clinical and genomic features, including 72% with visceral metastases, 50% with prior fulvestrant exposure, 20% with primary endocrine resistance, 42% harboring ESR1 mutations, and 50% harboring PIK3CA mutations. Treatment with the combination yielded a median progression-free survival (PFS) of 8.3 months (95% CI: 4.0–10.2) in the overall population. Subgroup analyses demonstrated prolonged PFS across molecular subtypes, showing 8.3 months (95% CI: 3.5–12.9) in ESR1-mutated tumors, 9.0 months (95% CI: 4.2–12.7) in ESR1 wild-type tumors, 8.3 months (95% CI: 3.6–10.2) in PIK3CA-mutated tumors, and 9.4 months (95% CI: 4.0–NR) in PIK3CA wild-type tumors. Adverse events were predominantly grade 1 or 2 and aligned with the established safety profiles of everolimus plus standard endocrine therapy. Treatment discontinuation due to adverse events occurred in 6% of patients, and dose reductions were required in 2%. These results support elacestrant as an effective endocrine backbone for combination targeted therapies targeting the PI3K/AKT/mTOR pathway in pretreated ER+/HER2- advanced breast cancer.

    Key Takeaways

    • In the Phase 2 ELEVATE trial cohort, elacestrant 345 mg plus everolimus 7.5 mg achieved a median progression-free survival of 8.3 months overall in patients with pretreated ER+/HER2- advanced breast cancer, with consistent outcomes in ESR1-mutated (8.3 months) and ESR1 wild-type (9.0 months) subgroups.
    • Progression-free survival benefit was maintained regardless of PIK3CA status, demonstrating a median PFS of 8.3 months in PIK3CA-mutated and 9.4 months in PIK3CA wild-type tumors.
    • The combination safety profile was consistent with known everolimus toxicity, consisting mostly of grade 1-2 adverse events, with overall treatment discontinuation and dose reduction rates of 6% and 2%, respectively.